Phasei Study News Today

Currently, the drug is being evaluated in a phase 1 clinical trial to determine the safety and efficacy in patients.

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for

NKGen Biotech, Inc. announced an online publication, titled ?Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity...

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...

LONDON, May 16 /PRNewswire/ -- Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the companys oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicag

SAN JOSE, Calif., Oct. 12, 2023 -- Rani Therapeutics Holdings, Inc. , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will...

This article outlines the powerful role of biomarkers in precision medicine, such as the use of autoantibodies for drug discovery against cancer.

/PRNewswire/ -- The "Phase I Market Outlook: 2022-2026" report has been added to ResearchAndMarkets.coms offering. The goal of this report is to provide...

-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022(NYSE American: SYN), a diversified

Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia